Search results
Showing 7396 to 7410 of 8212 results
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315
Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer [ID1404]
Discontinued Reference number: GID-TA10327
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy [ID1260]
Discontinued Reference number: GID-TA10309
Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]
Discontinued Reference number: GID-TA10330
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
Discontinued Reference number: GID-TA10295
Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer [ID1357]
Discontinued Reference number: GID-TA10322
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353
Discontinued Reference number: GID-TA10320
Discontinued Reference number: GID-TA10271
Guadecitabine for untreated acute myeloid leukaemia [ID1411]
Discontinued Reference number: GID-TA10325
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (DG45)
We have moved Diagnostics guidance 45 to become HealthTech guidance 610. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (DG46)
We have moved Diagnostics guidance 46 to become HealthTech guidance 611. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 47 to become HealthTech guidance 619. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care (DG48)
We have moved Diagnostics guidance 48 to become HealthTech guidance 682. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
PLGF-based testing to help diagnose suspected preterm pre-eclampsia (DG49)
We have moved Diagnostics guidance 49 to become HealthTech guidance 630. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved Diagnostics guidance 5 to become HealthTech guidance 291. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.